Cancer, General clinical trials at UCLA
48 in progress, 22 open to eligible people
KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
open to eligible people ages 18 years and up
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: 1. What is the safety of KVA12123 when…
Santa Monica, California and other locations
CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: - To assess the safety and tolerability of…
Santa Monica, California and other locations
Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care…
Los Angeles, California and other locations
SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
open to eligible people ages 18 years and up
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Los Angeles, California and other locations
NST-628 Oral Tablets in Subjects with Solid Tumors
open to eligible people ages 18 years and up
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid …
Westwood, California and other locations
Abatacept in Immune Checkpoint Inhibitor Myocarditis
open to eligible people ages 18 years and up
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The…
Los Angeles, California and other locations
RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
open to eligible people ages 18 years and up
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine…
Santa Monica, California and other locations
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
open to eligible people ages 18 years and up
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or…
Los Angeles, California and other locations
Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
open to eligible people ages 18 years and up
TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, …
Santa Monica, California and other locations
FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
open to eligible people ages 18 years and up
This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers…
Los Angeles, California
AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
open to eligible people ages 18 years and up
The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies.
Santa Monica, California and other locations
INKmune in Patients With mCRPC (CaRe Prostate)
open to eligible males ages 18 years and up
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Los Angeles, California and other locations
RP1 Monotherapy and RP1 in Combination With Nivolumab
open to eligible people ages 18 years and up
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and…
Los Angeles, California and other locations
DFP-14927 in Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.
Los Angeles, California and other locations
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
open to eligible people ages 40-80
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast…
Los Angeles, California
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
open to eligible people ages 18 years and up
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make…
Santa Monica, California and other locations
SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
open to eligible people ages 18 years and up
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Santa Monica, California and other locations
A2B530, a Logic-gated CAR T, in Participants with Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
open to eligible people ages 18 years and up
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that…
Los Angeles, California and other locations
A2B694, a Logic-gated CAR T, in Participants with Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
open to eligible people ages 18 years and up
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA),…
Los Angeles, California and other locations
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
open to eligible females ages 45-80
The purpose of this research is to develop a culturally adapted "Faith in Action!" curriculum to train lay health navigators to provide breast cancer screening navigation to Korean American women within faith-based settings and evaluate whether the…
Los Angeles, California and other locations
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
open to eligible females ages 30-74
Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40.…
Los Angeles, California and other locations
Childhood Cancer Survivor Study
open to all eligible people
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the…
Los Angeles, California and other locations
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Sorry, in progress, not accepting new patients
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte…
Los Angeles, California and other locations
Colorectal Cancer Screening in Cystic Fibrosis
Sorry, in progress, not accepting new patients
This multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer screening with colonoscopy. The primary endpoint is detection of any…
Los Angeles, California and other locations
(Peak) a Phase 3 Randomized Trial of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Gastrointestinal Stromal Tumors
Sorry, not currently recruiting here
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an…
Los Angeles, California and other locations
Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma
Sorry, in progress, not accepting new patients
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous…
Los Angeles, California and other locations
Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Sorry, in progress, not accepting new patients
This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored…
Los Angeles, California and other locations
A2B395, an Allogeneic Logic-gated CAR T, in Participants with Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Sorry, not yet accepting patients
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC),…
Los Angeles, California and other locations
LYL797 in Adults With Solid Tumors
Sorry, in progress, not accepting new patients
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial …
Santa Monica, California and other locations
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Sorry, in progress, not accepting new patients
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
Los Angeles, California and other locations
Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Sorry, in progress, not accepting new patients
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Los Angeles, California and other locations
TheraSphere Prostate Cancer (PCa) Device
Sorry, not currently recruiting here
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.
Los Angeles, California and other locations
Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups
Sorry, in progress, not accepting new patients
This clinical trial implements research strategies to increase colorectal cancer (CRC) screening rates among low income and ethnic minority groups. CRC is the second most common cause of cancer mortality in the United States and disproportionately…
Los Angeles, California
Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Sorry, in progress, not accepting new patients
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Los Angeles, California and other locations
Researching the Effect of Aerobic Exercise on Cancer
Sorry, in progress, not accepting new patients
This study is being done to answer the following question: Will aerobic exercise (exercise that stimulates and strengthens the heart and lungs, and improves the body's use of oxygen) change the biomarkers (signs of disease) found in the blood?
Los Angeles, California and other locations
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
Sorry, accepting new patients by invitation only
The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged…
Los Angeles, California and other locations
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
Sorry, not yet accepting patients
The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging…
Los Angeles, California and other locations
ART0380 in Patients With Biologically Selected Solid Tumors
Sorry, in progress, not accepting new patients
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).
Los Angeles, California and other locations
BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Sorry, in progress, not accepting new patients
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
Los Angeles, California and other locations
NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
Sorry, in progress, not accepting new patients
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.
Santa Monica, California and other locations
PC14586 in Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Sorry, not currently recruiting here
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1…
Los Angeles, California and other locations
UC Health Care Planning Study
Sorry, in progress, not accepting new patients
Using a cluster randomized design at the clinic level, this project will implement and test three real-world, scalable advance care planning interventions among primary care clinics across three University of California health systems. Seriously ill …
Los Angeles, California and other locations
UCLA Health Patient Health Maintenance Outreach Text Message
Sorry, in progress, not accepting new patients
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text messages impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA Health's …
Los Angeles, California
UCLA Health Patient Health Maintenance Text Reminder
Sorry, in progress, not accepting new patients
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text message reminders impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA …
Los Angeles, California
UCLA Health Patient Health Maintenance Text Reminder July 2023
Sorry, in progress, not accepting new patients
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text message reminders impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA …
Los Angeles, California
UCLA Health Patient Health Maintenance With Interactive Text Reminder
Sorry, in progress, not accepting new patients
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text message reminders impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA …
Los Angeles, California
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Sorry, not accepting new patients
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Torrance, California and other locations
Serial PET MPI in Patients Undergoing Cancer Treatment
Sorry, accepting new patients by invitation only
This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.
Los Angeles, California
Our lead scientists for Cancer, General research studies include Grant Turner, MD Rene Packard, MD, PhD Ashley E. Prosper, MD Eric H. Yang, MD Richard K. Leuchter, MD Jeremie Calais Jacqueline Casillas, MD J. Randolph Hecht, MD Neil S Wenger, MD Marla D. Lipsyc-Sharf, MD Zev A. Wainberg, MD Bartosz Chmielowski, MD, PhD Deborah J. Wong, MD, PhD Jonathan Goldman, MD Lee S. Rosen, MD Arash Naeim, MD, PhD Matthew B. Rettig, MD.
Last updated: